SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Verberk Inge)
 

Sökning: WFRF:(Verberk Inge) > Combination of plas...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005514naa a2200541 4500
001oai:lup.lub.lu.se:3531247a-6ec9-4101-85d6-25d1f4a9cabe
003SwePub
008201027s2020 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/3531247a-6ec9-4101-85d6-25d1f4a9cabe2 URI
0247 a https://doi.org/10.1186/s13195-020-00682-72 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Verberk, Inge M.W.u Vrije Universiteit Amsterdam4 aut
2451 0a Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
264 c 2020-09-28
264 1b Springer Science and Business Media LLC,c 2020
520 a Background: Blood-based biomarkers for Alzheimer's disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta(1-42/1-40), glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) to identify cerebral amyloidosis and/or disease severity. Methods: We included individuals with a positive (n = 176: 63 ± 7 years, 87 (49%) females) or negative (n = 76: 61 ± 9 years, 27 (36%) females) amyloid PET status, with syndrome diagnosis subjective cognitive decline (18 PET+, 25 PET-), mild cognitive impairment (26 PET+, 24 PET-), or AD-dementia (132 PET+). Plasma Abeta(1-42/1-40), GFAP, and NfL were measured by Simoa. We applied two-way ANOVA adjusted for age and sex to investigate the associations of the plasma markers with amyloid PET status and syndrome diagnosis; logistic regression analysis with Wald's backward selection to identify an optimal panel that identifies amyloid PET positivity; age, sex, and education-adjusted linear regression analysis to investigate associations between the plasma markers and neuropsychological test performance; and Spearman's correlation analysis to investigate associations between the plasma markers and medial temporal lobe atrophy (MTA). Results: Abeta(1-42/1-40) and GFAP independently associated with amyloid PET status (p = 0.009 and p < 0.001 respectively), and GFAP and NfL independently associated with syndrome diagnosis (p = 0.001 and p = 0.048 respectively). The optimal panel identifying a positive amyloid status included Abeta(1-42/1-40) and GFAP, alongside age and APOE (AUC = 88% (95% CI 83-93%), 82% sensitivity, 86% specificity), while excluding NfL and sex. GFAP and NfL robustly associated with cognitive performance on global cognition and all major cognitive domains (GFAP: range standardized β (sβ) = - 0.40 to - 0.26; NfL: range sβ = - 0.35 to - 0.18; all: p < 0.002), whereas Abeta(1-42/1-40) associated with global cognition, memory, attention, and executive functioning (range sβ = 0.22 - 0.11; all: p < 0.05) but not language. GFAP and NfL showed moderate positive correlations with MTA (both: Spearman's rho> 0.33, p < 0.001). Abeta(1-42/1-40) showed a moderate negative correlation with MTA (Spearman's rho = - 0.24, p = 0.001). Discussion and conclusions: Combination of plasma Abeta(1-42/1-40) and GFAP provides a valuable tool for the identification of amyloid PET status. Furthermore, plasma GFAP and NfL associate with various disease severity measures suggesting potential for disease monitoring.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Klinisk laboratoriemedicin0 (SwePub)302232 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Clinical Laboratory Medicine0 (SwePub)302232 hsv//eng
653 a Alzheimer's continuum
653 a Amyloid pathology
653 a Blood-based biomarkers
653 a Plasma amyloid beta
653 a Plasma GFAP
7001 a Thijssen, Elisabethu Vrije Universiteit Amsterdam4 aut
7001 a Koelewijn, Jannetu Vrije Universiteit Amsterdam4 aut
7001 a Mauroo, Kimberleyu ADx NeuroSciences4 aut
7001 a Vanbrabant, Jeroenu ADx NeuroSciences4 aut
7001 a De Wilde, Arnou Vrije Universiteit Amsterdam4 aut
7001 a Zwan, Marissa D.u Vrije Universiteit Amsterdam4 aut
7001 a Verfaillie, Sander C.J.u Vrije Universiteit Amsterdam4 aut
7001 a Ossenkoppele, Riku Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Vrije Universiteit Amsterdam4 aut0 (Swepub:lu)ri1513os
7001 a Barkhof, Frederiku University College London4 aut
7001 a Van Berckel, Bart N.M.u Vrije Universiteit Amsterdam4 aut
7001 a Scheltens, Philipu Vrije Universiteit Amsterdam4 aut
7001 a Van Der Flier, Wiesje M.u Vrije Universiteit Amsterdam4 aut
7001 a Stoops, Eriku ADx NeuroSciences4 aut
7001 a Vanderstichele, Hugo M.u ADx NeuroSciences4 aut
7001 a Teunissen, Charlotte E.u Vrije Universiteit Amsterdam4 aut
7102 a Vrije Universiteit Amsterdamb ADx NeuroSciences4 org
7730 t Alzheimer's Research and Therapyd : Springer Science and Business Media LLCg 12:1q 12:1x 1758-9193
8564 u http://dx.doi.org/10.1186/s13195-020-00682-7x freey FULLTEXT
8564 u https://alzres.biomedcentral.com/track/pdf/10.1186/s13195-020-00682-7
8564 8u https://lup.lub.lu.se/record/3531247a-6ec9-4101-85d6-25d1f4a9cabe
8564 8u https://doi.org/10.1186/s13195-020-00682-7

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy